anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study evaluates biopsychosocial factors as mediators of the effect of chiropractic care on low back pain (LBP) intensity and interference for active-duty military members. Data from a multi-site, pragmatic clinical trial comparing six weeks of chiropractic care plus usual medical care to usual medical care alone for 750 US active-duty military members with LBP were analyzed using natural-effect, multiple-mediator modeling. Mediation of the adjusted mean effect difference on 12-week outcomes of PROMIS-29 pain interference and intensity by 6-week mediators of other PROMIS-29 physical, mental, and social health subdomains was evaluated. The effect difference on pain interference occurring through PROMIS-29 biopsychosocial factors (natural indirect effect = -1.59, 95% CI = -2.28 to -0.88) was 56% (95% CI = 35 to 96) of the total effect (-2.82, 95% CI = -3.98 to -1.53). The difference in effect on pain intensity occurring through biopsychosocial factors was smaller (natural indirect effect = -0.32, 95% CI = -0.50 to -0.18), equaling 26% (95% CI = 15 to 42) of the total effect (-1.23, 95% CI = -1.52 to -0.88). When considered individually, all physical, mental, and social health factors appeared to mediate the effect difference on pain interference and pain intensity with mental health factors having smaller effect estimates. In contrast with effects on pain interference, much of the effect of adding chiropractic care to usual medical care for US military members on pain intensity did not appear to occur through the PROMIS-29 biopsychosocial factors. Physical and social factors appear to be important intermediate measures for patients receiving chiropractic care for low back pain in military settings. Further study is needed to determine if the effect of chiropractic care on pain intensity for active-duty military occurs through other unmeasured factors, such as patient beliefs, or if the effect occurs directly.
Patients regularly have casts, splints, and wounds that require attention in the clinic. Patients commonly experience anxiety and pain during such visits. We hypothesized that aromatherapy and music would improve these patients' pain and anxiety when compared with no exposure. Patients in the orthopedic cast room were randomly exposed to no experience, music, or aromatherapy. Postprocedural surveys using an abbreviated form of the Spielberger State-Trait Anxiety Inventory (5 items; 4-point Likert scale) and a visual analog scale (0 to 10) were used to collect patient perceptions that were then compared using Spearman rank correlation calculations, t tests, and ordinal regression. Correlation results for the anxiety inventory were not different for patients with music or aromatherapy exposure vs no exposure; however, lower anxiety inventory scores were correlated with lower pain scores for upset, frightened, nervous, and confused measures. Mean reported pain scores were statistically lower for patients exposed to music (3.0) or aromatherapy (3.9) compared with patients who had no exposure (5.1; P=.004). These results support our hypothesis that exposure to music or aromatherapy improves pain. Although neither music nor aromatherapy resulted in significantly lower scores on the anxiety inventory items, the attention to patients' pain could have an indirect effect on their anxiety. [Orthopedics. 2024;47(2):e90-e92.].
PURPOSE:To prepare an HIV superinfection preventive by preventing the cells persistently infected with HIV from being infected again with HIV whereby the cells can be avoided from converting into those producing highly toxic viruses. CONSTITUTION:The HIV superinfection preventive is the peptides comprising the amino acid sequence, counting from the N-terminus of human CD 4 molecule, from No.66 to No.92 (formula I), from No.68 to No.130 (formula II), and from No.84 to No. 120, further peptides of formulas I and II where the No. 84 Cys counted from the N-terminus is modified with Acm(acetamidemethyl) or Bzl(benzyl). Another HIV superinfection preventive contains monoclonal antibody reactive with the peptides having the amino acid sequences of formula I or formula II. The monoclonal antibody can be also used as an antigen for preparing anti-idiotype antibody and anti-idiotype antibody ID55 (FERM-BP-3165), ID-62 (FERM-BP-3166) effective as an HIV superinfection preventive can be obtained by effecting immunization using the antibody as an antigen.
MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will then be instructed to consume 200 mg caffeine in tablet form. This is equivalent to the caffeine content of an 8 oz brewed coffee from Starbucks. After 45 minutes after consumption of the caffeine tablet, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
SABR is delivered to all sites of progressive disease with continuation of current systemic agents. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in Arm 1.
Up to 200 symptomatic subjects (index cases) will be enrolled when they seek diagnosis for their symptoms of COVID-19 and have their SARS-CoV-2 infection confirmed. All their household contacts (anticipated 700) aged 5-75 years who provide consent (participants) will be examined for infection through two consecutive SARS-CoV-2 RT-PCR. Blood will be drawn from all participants who provide consent. Venous Blood will be drawn at the first visit (so called W0). A second collection is planned for 15 days after the first visit, a third collection at three months after the first visit, and subsequent collections are planned at six, nine, and 15 months after the first visit. At the visits one month, nine months and 15 months after the first visit, capillary blood will be collected. A stool sample will be collected for diagnosis of intestinal parasites.
The invention provides a preparation method of a radix salviae miltiorrhizae cellwall-broken decoction piece. The preparation method comprises the following steps: picking and choosing medicinal materials and cleaning/processing, drying, breaking, crushing by a pulverizer with 100-mesh sieve, carrying out batch-type sterilization, breaking cell walls, pelletizing, and drying to prepare the radix salviae miltiorrhizae cellwall-broken decoction piece. The prepared decoction piece has good grain shape and moderate degree of tightness. In addition, the prepared granules are easy to dry, is rapid to dissolve and disperse, and is easy to disperse when being taken by a user. The batch-type sterilization meets the requirement of microbial limit. The problem that radix salviae miltiorrhizae cellwall-broken decoction pieces on the current market are hard to dissolve and disperse and microbial limit is difficult to reach the standard is solved.
The subject invention concerns methods for preparing alkaline earth ferrates. In one embodiment, the alkaline earth ferrate is barium ferrate. In another embodiment, the alkaline earth ferrate is strontium ferrate. In one embodiment, methods of the invention comprise heat treating mixtures of alkaline earth oxides and/or peroxides with iron oxides, such as hematite or magnetite. In another embodiment, alkaline earth ferrates are produced by heating mixtures of alkaline earth nitrates and iron oxides. The subject invention also concerns hemostatic compositions produced using manganese oxides or metallic oxides that are reacted with alkaline earth oxides and/or peroxides and the methods used to produce the hemostatic compositions.
The primary objective is to evaluate whether the intensity of treatment adherence support affects sustained virologic response rates in HCV mono- and HIV/HCV co-infected participants receiving HCV direct-acting antivirals (DAA) in PWID-focused centers. Secondary objectives are: 1. To evaluate whether the intensity of treatment adherence support affects HCV treatment completion rates. 2. To evaluate whether the intensity of treatment adherence support affects HCV treatment adherence. 3. To estimate the incidence and correlates of HCV reinfection among HCV mono- and HIV/HCV coinfected PWID who achieve HCV cure. 4. To evaluate the impact of HCV cure on HIV viral suppression among HIV/HCV coinfected PWID.

Investigators will evaluate this via a 3-arm, individual-level randomized clinical trial, in which treatment assignment probabilities vary according to participants' estimated propensity for treatment failure at baseline (precision randomization). An estimated 3,000 persons will be enrolled and randomized at 7 community-based integrated care centers (ICCs) across India across a duration of 18 - 24 months. Data from these 7 ICCs on early HIV treatment refills/viral suppression (3-6 months after antiretroviral therapy (ART) initiation) will be used to develop and validate an algorithm to predict propensity for HCV treatment failure. Prior to treatment initiation, each participant will undergo a questionnaire to capture information on barriers/ facilitators to treatment adherence identified in the prediction model in order to determine the propensity for HCV treatment failure (minimal or elevated risk). Individuals will be preferentially randomized to the support level that matches their failure risk. Those at elevated risk for treatment failure will be randomized at an allocation ratio of 3:2:1 for Arm 3 (high intensity support), Arm 2 (medium intensity support) and Arm 1 (low intensity support), respectively. Conversely, those at minimal risk will be randomized at a ratio of 1:2:3 to Arm 3 (high intensity support), Arm 2 (medium intensity support) and Arm 1 (low intensity support), respectively. Participants and study staff will be blinded to the risk classification (minimal, elevated) but, because of the nature of the interventions, blinding to intervention assignment is not possible.

Persons will be treated for HCV according to the standard of care in India. Minimal laboratory monitoring will be used except when clinically indicated. Participants with decompensated cirrhosis will be excluded from treatment.

All HIV/HCV co-infected participants and those HCV monoinfected participants who achieve SVR will be followed post-treatment. These individuals will be followed every six months after the SVR assessment to assess HCV reinfection and HIV viral suppression (among HIV/HCV coinfected participants) for up to 30 months after SVR.
Participants will receive TDF plus GS-4774 10 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
INTRODUCTION: To determine associations between prostate cancer (PCa) tumor burden measured on biopsy or multiparametric magnetic resonance imaging (mpMRI) and outcomes in intermediate-risk (IR) International Society of Urological Pathology (ISUP) grade 2 men managed with primary radical prostatectomy (RP).
METHODS: This retrospective, multicenter study was conducted in eight referral centers. The cohort included IR PCa patients who had ISUP 2 at biopsy. We defined biopsy tumor burden as low/high based on the absence/presence of more than 25% positive cores. Tumor burden on imaging was defined as low/high based on maximum lesion diameter, <15 mm and ≥15 mm at mpMRI, respectively. The histological endpoint of the study was adverse features at RP, defined as ≥pT3a stage and/or lymph node invasion and/or ISUP ≥3 at final pathology. The clinical endpoint was biochemical recurrence (BCR) after RP.
RESULTS: A total of 698 IR patients was included, of whom 335 (48%) had adverse features. In multivariate logistic regression analysis, there was no statistical association between tumor burden at biopsy and adverse features (p = 0.7). Tumor size ≥15 mm at mpMRI was significantly associated with adverse pathology (OR 1.65, 95%CI 1.14-2.39; p = 0.01). No significant association was observed between tumor burden at biopsy and BCR (p = 0.4). Tumor size ≥15 mm at mpMRI was significantly associated with BCR (HR 1.96, 95% CI 1.01-3.80; p = 0.04).
CONCLUSIONS: Our data support extending the inclusion criteria to ISUP 2 men with >25% positive cores, provided they have a low tumor size at mpMRI (<15 mm). Prospective studies should be performed to validate these findings.
Topiramate will be introduced 25 mg/day b.i.d. for the first week and increased to 100 mg/day b.i.d. for the second week.
The influence of TF, endothelial cell protein C receptor (EPCR) and protease activated receptor-1 (PAR1) on tumor growth of malignant pleural mesothelioma (MPM) is disclosed. MPM cells that lack or express TF, EPCR or PAR1 and a murine orthotopic model of MPM led to the discovery that intrapleural administration into nude mice of REN MPM cells expressing TF and PAR1 but lacking EPCR and PAR2 generated large pleural cavity tumors. Suppression of TF or PAR1 expression markedly reduced tumor growth. Overexpression of TF in non-aggressive MPM cells expressing EPCR and PAR1 but exhibiting minimal levels of TF failed to alter their tumorigenicity. Introduction of EPCR expression in aggressive MPM cells attenuated tumor growth whereas EPCR silencing in non-aggressive MPM cells overexpressing TF increased tumorigenicity of non-aggressive cells. Expression of EPCR by MPM cells suppresses tumor growth and treats MPM.
Capsule administration. Six subjects will be recruited in each cohort. safety data up to day 14 will be evaluated. Single dose will be administered in ascending manner starting from 12.5 mg.
Our understanding of rare disease genetics has been shaped by a monogenic disease model. While the traditional monogenic disease model has been successful in identifying numerous disease-associated genes and significantly enlarged our knowledge in the field of human genetics, it has limitations in explaining phenomena like phenotypic variability and reduced penetrance. Widening the perspective beyond Mendelian inheritance has the potential to enable a better understanding of disease complexity in rare disorders. Digenic inheritance is the simplest instance of a non-Mendelian disorder, characterized by the functional interplay of variants in two disease-contributing genes. Known digenic disease causes show a range of pathomechanisms underlying digenic interplay, including direct and indirect gene product interactions as well as epigenetic modifications. This review aims to systematically explore the background of digenic inheritance in rare disorders, the approaches and challenges when investigating digenic inheritance, and the current evidence for digenic inheritance in mitochondrial disorders.
This is an epidemiologic study of the incidence of severe RSV LRTI among Brazilian children born \<35WGA. The study will enroll competitively 350 subjects from 3 sites in Brazil. Preterm children will be identified after birth and up to 72 hours after hospital discharge and followed for one year after the enrollment. Subjects will be seen monthly for the first 6 months and bimonthly until one year of follow-up. At each visit, a medical and social history will be updated and a physical examination will be performed. Legal representative will notify study personnel in the event of a respiratory illness or hospital admission at which time the subject will be seen by an investigator. Children with LRTI diagnosed by physical examination will have viral diagnostic tests performed. Subjects with a LRTI not requiring hospitalization will be followed by telephone weekly until illness resolution. Hospitalized children with a LRTI will be followed daily while hospitalized and followed by telephone until illness resolution. All medical interventions and outcomes will be recorded.
AIM: This study aims to elucidate what volunteering activities mean for older adults in Japan by analyzing their emotions and evaluations from hedonic (e.g., happiness), eudaimonic (e.g., self-growth), and social (e.g., social coherence) well-being.
METHODS: The qualitative research was conducted to describe the subjective experience of older adults' volunteering activities (frailty checkups) in the community-setting. Eight older adults were interviewed about their experiences during these activities. The interview data were analyzed from two assumption frameworks: first, three aspects of well-being, and second, timeframes of well-being, during the activity, medium-term, and long-term. Previous studies have not focused on the polysemy or the timeframe of well-being.
RESULTS: Our results showed that hedonic, eudaimonic, and social well-being are not independent, but overlap. Furthermore, even if older adults experience certain emotions at a point of time, they may change in the long term. This implies that it is important to analyze older adults' feelings and experiences from not only one aspect but from different perspectives and measure their feelings not just at a particular moment but in the long term. This is the first empirical study to examine qualitatively the holistic experiences of well-being among older adults who volunteer.
CONCLUSIONS: We conclude that this study is unique in that it attempted to associate empirically the experiences of older adults during volunteering with their general psychological status of well-being. These findings could help make volunteering activities more meaningful for older adults and create or promote an active community. Geriatr Gerontol Int 2024; 24: 273-278.
Neck pain is common, and return to duty rates after medical evacuation from theater for spinal pain is low. Muscles comprise the majority of the stability for the cervical spine, yet neck muscle function can be altered in the presence of pain. Research has consistently shown the benefit of including thoracic spine manipulation (SMT) in the treatment of patients with mechanical neck pain. Emerging evidence is now also showing promising benefit of including trigger point dry needling (TDN) for the treatment of mechanical neck pain. Treatment regimens commonly address anterior cervical stabilizing musculature, but little is known regarding the response to treatment of the deep posterior stabilizing musculature.

This study will assess the short term response of thoracic SMT with or without TDN in 58 subjects with a primary complaint of mechanical neck pain. Subjects will be randomized to receive 2 treatment visits approximately 2-3 days apart of either SMT+sham TDN or SMT+TDN. TDN will be directed to the upper trapezius and deep cervical extensor muscles of the neck. Outcomes of interest will be changes in function and pain. Assessments will be made at baseline, immediately after the first treatment, at the 2nd treatment, and approximately 5-7 days after the 2nd treatment visit. A subgroup of 20 subjects (10 per group) will also have the upper trapezius and deep cervical extensor muscle activation assessed via shear wave elastography, and deep cervical flexor activation assessed via the craniocervical flexion test.
4-Halo-etianic acids and derivations of the formula: < CHEM > wherein X<1> is fluoro or chloro X<2> is fluoro, chloro or hydrogen X<3> is fluoro, chloro, bromo or hydrogen X<4> is =C=O or < CHEM > of may be < CHEM > when X<3> is chloro R is hydrogen, alkyl of one to six carbon atoms optionally substituted with one halo, or phenyl or benzyl optionally substituted on the phenyl ring with a substituent selected from alkyl of one to four carbon atoms, alkoxy of one to four atoms and halo R<1> is hydrogen or alkanoyl of 2 to 6 carbon atoms R<2> is hydrogen, alpha -methyl or beta -methyl and the solid and broken lines between C-1 and C-2 represent a double or a single bond. The compounds wherein R is other than hydrogen are useful as anti-inflammatory agents. They can be prepared by esterifying the corresponding acid. The 17 alpha -esters can be prepared by esterifying the corresponding 17 alpha -hydroxy compounds. The 17ss-carboxylic group can be introduced by oxidising the corresponding 20-oxo-21-hydroxy (or alkanoyloxy) compound. The double bond at the 4,5 position is produced by contacting the corresponding DELTA <5> compound with a base.
The invention relates to tablets used for preventing aspermia infertility. The tablets are current novel products specially used for preventing male infertility. Male infertility is caused by sperm abnormality. Sperm is an active substance produced in testis. In lives, a lot of male infertilities are caused by oligospermia or aspermia. The tablets are prepared from 25 Chinese herbal medicines such as tuber fleeceflower root, medlar, Chinese dodder seed, and Chinese magnoliavine fruit. The tablets contain various plant polysaccharide components, which contain different trace elements. The trace elements assist in promoting sperm growth and enhancing sperm activity. Therefore, the tablets provide substantial treatment effects upon male infertilities caused by oligospermia and aspermia.
Disruption of lipoprotein metabolism plays an important role in the development of several cardiovascular, inflammatory, and metabolic diseases. This review examines the importance of different types of lipoproteins and the role they play in the development of dyslipidemia in obesity. The causes and consequences associated with the disruption of lipid metabolism and its significance in the pathogenesis of obesity are considered. The relationship between such pathological processes, which occur alongside obesity as dyslipidemia and inflammation, is determined. In view of the current efficacy and toxicity limitations of currently approved drugs, natural compounds as potential therapeutic agents in the treatment of obesity are considered in the review. The complex mechanisms of lipid metabolism normalization in obesity found for these compounds can serve as one of the confirmations of their potential efficacy in treating obesity. Nanoparticles can serve as carriers for the considered drugs, which can improve their pharmacokinetic properties.
The present disclosure provides for methods and an apparatus to provide an adhesive securing patch to keep a monitoring system or other apparatus pressed against a body part. Generally, a wearable medical device is pressed against or into a patient. A first flexible substrate layer is applied to the wearable medical device to secure it against the patient's skin. The flexibility of this substrate layer creates a cavity for any supracutaneous portion of the medical device. A second adhesive substrate layer is applied to secure the first substrate layer, as well as to provide a visual display, such as medical information or an image. A third, larger, transparent substrate layer is applied to secure the first and second substrate layers and to allow for exterior viewing of the visual display of the second substrate layer.